BRPI0514297A - composições farmacêuticas para liberação controlada de compostos biologicamente ativos - Google Patents

composições farmacêuticas para liberação controlada de compostos biologicamente ativos

Info

Publication number
BRPI0514297A
BRPI0514297A BRPI0514297-0A BRPI0514297A BRPI0514297A BR PI0514297 A BRPI0514297 A BR PI0514297A BR PI0514297 A BRPI0514297 A BR PI0514297A BR PI0514297 A BRPI0514297 A BR PI0514297A
Authority
BR
Brazil
Prior art keywords
biologically active
controlled release
active compounds
methods
provides
Prior art date
Application number
BRPI0514297-0A
Other languages
English (en)
Inventor
Li Yuhua
Benjamin Chien
Original Assignee
Quest Pharmaceutical Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmaceutical Services filed Critical Quest Pharmaceutical Services
Publication of BRPI0514297A publication Critical patent/BRPI0514297A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

COMPOSIçõES FARMACêUTICAS PARA LIBERAçãO CONTROLADA DE COMPOSTOS BIOLOGICAMENTE ATIVOS A presente invenção fornece composições e métodos para a liberação controlada de um ou mais compostos biologicamente ativos a um indivíduo. Especificamente, a invenção fornece uma composição farmacêutica para a liberação controlada de compostos biologicamente ativos a um indivíduo que compreende: a) um complexo de um composto biologicamente ativo tendo pelo menos um grupo funcional básico e um poliânion derivado de hexahidroxiciclohexano tendo pelo menos dois grupos funcionais negativamente carregados; e b) um veículo farmaceuticamente aceitável que compreende um polímero biodegradável, insolúvel em água por complexação de um composto biologicamente ativo com um poliânion, o complexo estável pode ser incorporado em um sistema de dosagem de ação longa tendo uma curva de liberação de medicamento sobre tempo mais desejada que aquela encontrada na técnica prévia. A invenção também fornece os métodos de fazer tais composições e os métodos de uso dessas.
BRPI0514297-0A 2004-08-12 2005-08-11 composições farmacêuticas para liberação controlada de compostos biologicamente ativos BRPI0514297A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60090704P 2004-08-12 2004-08-12
PCT/US2005/028676 WO2006017852A2 (en) 2004-08-12 2005-08-11 Pharmaceutical compositions for controlled release delivery of biologically active compounds

Publications (1)

Publication Number Publication Date
BRPI0514297A true BRPI0514297A (pt) 2008-06-10

Family

ID=35839986

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514297-0A BRPI0514297A (pt) 2004-08-12 2005-08-11 composições farmacêuticas para liberação controlada de compostos biologicamente ativos

Country Status (21)

Country Link
US (1) US7964219B2 (pt)
EP (1) EP1786400B1 (pt)
JP (1) JP5053846B2 (pt)
KR (1) KR101231856B1 (pt)
CN (1) CN101035512B (pt)
AT (1) ATE424848T1 (pt)
AU (1) AU2005271242B9 (pt)
BR (1) BRPI0514297A (pt)
CA (1) CA2576689C (pt)
CY (1) CY1109425T1 (pt)
DE (1) DE602005013244D1 (pt)
DK (1) DK1786400T3 (pt)
ES (1) ES2323141T3 (pt)
HK (1) HK1108638A1 (pt)
MX (1) MX2007001760A (pt)
NZ (1) NZ553149A (pt)
PL (1) PL1786400T3 (pt)
PT (1) PT1786400E (pt)
RU (1) RU2390355C2 (pt)
SI (1) SI1786400T1 (pt)
WO (1) WO2006017852A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786400B1 (en) * 2004-08-12 2009-03-11 Quest Pharmaceutical Services Pharmaceutical compositions for controlled release delivery of biologically active compounds
ITRM20050344A1 (it) * 2005-06-30 2007-01-01 Luca Maria De Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
EP1971362B1 (en) 2005-08-19 2014-12-03 Amylin Pharmaceuticals, LLC Exendin for treating diabetes and reducing body weight
PT1968549E (pt) * 2005-12-22 2014-08-29 Novartis Ag Formulação de libertação controlada compreendendo octreotida e dois ou mais polímeros de polilactídeo-co-glicolídeo
EP1984009B1 (en) * 2006-01-18 2012-10-24 Qps, Llc Pharmaceutical compositions with enhanced stability
PT2034951E (pt) 2006-06-22 2013-04-18 Biocompatibles Uk Ltd Produto farmacêutico reidratável
EP1917971A1 (en) 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
MX2009011123A (es) * 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
CA2698824A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
US8551072B2 (en) 2007-12-12 2013-10-08 Boston Scientific Scimed, Inc. Methods, devices and compositions for controlled drug delivery to injured myocardium
BRPI0905707B1 (pt) * 2008-01-18 2024-02-27 Dow Global Technologies Inc Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
EP2213307A1 (en) * 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
ES2600797T3 (es) * 2008-08-12 2017-02-10 Novartis Ag Composiciones farmacéuticas
KR101258336B1 (ko) 2008-10-02 2013-04-25 밀란 인크. 다층 접착제 라미네이트를 제조하는 방법
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
WO2010123563A2 (en) * 2009-04-23 2010-10-28 Sustained Nano Systems Llc Controlled release dispensing device
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
EP2475396A4 (en) * 2009-09-10 2013-10-16 Univ Pittsburgh ARTIFICIAL MICROPARTICLES FOR THE ADMINISTRATION OF MACROMOLECULES
NZ598686A (en) * 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CN107412749A (zh) * 2010-02-22 2017-12-01 优势医疗公司 治疗脑的出血性病状的方法和组合物
KR101319420B1 (ko) * 2011-03-18 2013-10-17 한남대학교 산학협력단 서방형 방출이 가능한 수용성 양이온 약물 전달 시스템
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
CN102552169B (zh) * 2012-02-17 2015-07-29 深圳市健元医药科技有限公司 一种醋酸阿肽地尔缓释微球制剂及其制备方法
BR112014028600B1 (pt) 2012-05-18 2022-11-22 Genentech, Inc Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
US9040034B2 (en) 2013-04-09 2015-05-26 International Business Machines Corporation Vitamin functionalized gel-forming block copolymers for biomedical applications
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
HUE037945T2 (hu) 2014-07-09 2018-09-28 Pf Medicament Eljárás mozgási rendellenességek kezelésére befiradollal
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN107849110B (zh) * 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
CN109937046A (zh) 2016-09-09 2019-06-25 艾利西斯股份有限公司 脂质体抗癌组合物
EP3538131A4 (en) 2016-11-09 2020-07-01 Mayo Foundation for Medical Education and Research MANP ANALOG
DE102016013737A1 (de) * 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
CA3069159A1 (en) 2017-07-11 2019-01-17 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
CN111032054A (zh) 2017-07-11 2020-04-17 持续纳米系统有限责任公司 超压缩聚合物剂型的辐射灭菌
KR102137786B1 (ko) * 2018-07-19 2020-07-24 주식회사 아울바이오 주사제용 미립구의 제조방법
CN113164395A (zh) 2018-10-15 2021-07-23 株式会社钟根堂 注射用长效纳屈酮微粒组合物
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CN112661958B (zh) * 2020-12-09 2023-03-17 中山大学 一种基于肌醇和精氨酸的聚酯酰胺及其制备方法与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4578384A (en) * 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US6312679B1 (en) * 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US4728202A (en) * 1987-01-14 1988-03-01 Emerson Electric Co. Shaft locking collar for bearing assemblies
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JPH0426630A (ja) * 1990-05-19 1992-01-29 Wakiyou Kagaku Kogyo Kk 水性製剤におけるリゾチーム塩の安定化方法
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
ATE154240T1 (de) 1992-03-12 1997-06-15 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
ATE195652T1 (de) * 1992-12-02 2000-09-15 Alkermes Inc Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
WO1996021440A1 (en) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
US5698213A (en) * 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US6410044B1 (en) * 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
IL140017A (en) * 2000-11-30 2009-09-22 Abraham J Domb Polyhedra
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7226624B2 (en) * 2002-07-24 2007-06-05 Rabinowitz Israel N Synergistic compositions from yeast-modified aqueous extracts from almond hulls
WO2004017913A2 (en) * 2002-08-22 2004-03-04 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
WO2004035762A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
EP1786400B1 (en) * 2004-08-12 2009-03-11 Quest Pharmaceutical Services Pharmaceutical compositions for controlled release delivery of biologically active compounds

Also Published As

Publication number Publication date
AU2005271242A1 (en) 2006-02-16
DK1786400T3 (da) 2009-06-29
AU2005271242B2 (en) 2011-09-15
CN101035512A (zh) 2007-09-12
NZ553149A (en) 2010-01-29
PT1786400E (pt) 2009-06-19
CN101035512B (zh) 2012-01-18
WO2006017852A3 (en) 2006-08-31
CA2576689C (en) 2012-10-09
PL1786400T3 (pl) 2009-08-31
WO2006017852A2 (en) 2006-02-16
SI1786400T1 (sl) 2009-08-31
KR101231856B1 (ko) 2013-02-08
US20060034923A1 (en) 2006-02-16
MX2007001760A (es) 2007-07-24
US7964219B2 (en) 2011-06-21
ATE424848T1 (de) 2009-03-15
EP1786400A4 (en) 2008-07-09
JP2008511544A (ja) 2008-04-17
DE602005013244D1 (de) 2009-04-23
RU2390355C2 (ru) 2010-05-27
HK1108638A1 (en) 2008-05-16
EP1786400B1 (en) 2009-03-11
RU2007105872A (ru) 2008-09-20
JP5053846B2 (ja) 2012-10-24
CA2576689A1 (en) 2006-02-16
AU2005271242A2 (en) 2006-02-16
ES2323141T3 (es) 2009-07-07
CY1109425T1 (el) 2014-08-13
EP1786400A2 (en) 2007-05-23
AU2005271242B9 (en) 2012-04-12
KR20070043881A (ko) 2007-04-25

Similar Documents

Publication Publication Date Title
BRPI0514297A (pt) composições farmacêuticas para liberação controlada de compostos biologicamente ativos
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
WO2007084460A3 (en) Pharmaceutical compositions with enhanced stability
BR112013016772B8 (pt) compostos, uso do composto e composição farmacêutica
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
NZ610315A (en) Antiviral condensed heterocyclic compounds
WO2007048219A3 (en) Sustained drug release composition
WO2005034859A3 (en) Extended release formulations of opioids and method of use thereof
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
WO2004108162A3 (en) Controlled release pharmaceutical composition
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
GEP20115200B (en) Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
WO2009063222A3 (en) Solid compositions
HK1135923A1 (en) Pharmaceutical agent having long-lasting effect of treating arthritic disorders
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
HK1123986A1 (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
ATE359800T1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
MXPA06000760A (es) Composicion farmaceutica estable de carisoprodol y meloxicam.
MY148611A (en) Imino-imidazo-pyridine derivatives having antithrombotic activity

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FORESEE PHARMACEUTICALS, CO., LTD. (CN)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.